Metabolic Surgery for Type 2 Diabetes

Slides:



Advertisements
Similar presentations
LAGB in low BMI patients Jaime Ponce MD FACS FASMBS Dalton GA MISS Salt Lake City UT February 24, 2012.
Advertisements

Dr. Monica Nannipieri Dipartimento di Medicina Clinica e Sperimentale Università di Pisa.
Dr. Chris Cobourn Medical Director and Surgeon Surgical Weight Loss Centre Staff Surgeon Trillium Health Centre Mississauga, Ontario.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Remissione del diabete tipo 2: Terapia Medica Dr. Monica Nannipieri Dipartimento di Medicina Clinica e Sperimentale Università di Pisa.
Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Bariatric Surgery vs. Intensive Medical Therapy in Obese Diabetic Patients: 3-Year Outcome Bariatric Surgery vs. Intensive Medical Therapy in Obese Diabetic.
Effects of Gastric Bypass Surgery in Patients With Type 2 Diabetes and Only Mild Obesity Featured Article: Ricardo V. Cohen, M.D., Jose C. Pinheiro, M.D.,
Roles of Laparoscopic Sleeve Gastrectomy in Bariatric Surgery
Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
Why Surgical Treatment of Diabetes May Not be a Good Option McGill First Canadian Summit on Surgery for Type 2 Diabetes Montréal, Québec May 7, 2010 David.
Comparative Effectiveness of Bariatric Surgery and Nonsurgical Therapy in Adults With Metabolic Conditions and a Body Mass Index of 30.0 to 34.9 kg/m 2.
Bariatric Surgery for the Treatment of Obesity and Metabolic Disease
Obesity – Growing epidemic Center for Disease Control and Prevention 2006.
Beyond Dieting: New Weight Loss Medications & Treatments on the Horizon Daniel Bessesen, MD.
Bariatric Surgery in Obesity and Metabolic Disease Olivier Court MD FRCSC Director, section of Bariatric Surgery McGill University Health Center.
MALABSORPTIVE BARIATRIC SURGERY in Low BMI Korean Patients Ji Yeon Park Soonchunhyang University Seoul Hospital, Korea.
Safety of Ambulatory Bariatric Surgery Senapati PS, Menon A, Al-Rashedy M, Thawdar P, Akhtar K, Ammori BJ Department of Obesity and Metabolic Surgery Salford.
BARIATRIC (METABOLIC) SURGERY FOR LIFE-LONG WEIGHT CONTROL AND REMISSION OF ASSOCIATED CHRONIC DISEASES – A METAANALYSIS OF PUBLISHED CLINICAL PAPERS TO-DATE.
Post-Surgical Care of the Bariatric Patient
Minimally Invasive Surgery Symposium Modest Weight Loss in T2 DM: Lessons from the Look AHEAD Trial Donna H. Ryan, MD Pennington Biomedical Research Center.
Fight obesity with effective and guaranteed tools t Haitham Al-Khayat, MD Consultant general and bariatric surgeon New Dar Al-Shifa hospital.
Metabolic Surgery Abul Fazal Ali Khan Professor of Surgery Allama Iqbal Medical College Lahore.
Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.
Jaime Ponce MD, FACS, FASMBS Director of Bariatric Surgery Hamilton Medical Center Dalton Georgia USA LAGB Weight Loss and Diabetes 2010 Minimally Invasive.
MISS Journal Club 2012 Metabolic Surgery & Emerging Technologies Goal: To review 5 important and clinically relevant papers from 2011, on Metabolic Surgery.
Daniel Tat-ming Chung Princess Margaret Hospital 16 th April 2011 JHSGR.
Bariatric/Metabolic Surgery and Type 2 Diabetes September 2015 Deron Ludwig MD/Erik Simchuk MD North Valley Surgical Associates Chico, CA.
Ali Ardestani, David Rhoads, Ali Tavakkoli
Obesity Surgery : Is it only for losing weight ? Joint Hospital Surgical Grand Round Simon Chu Prince of Wales Hospital.
Bariatric Surgery and Metabolism Goal: to review 4 important and clinically relevant papers from 2010 on Bariatric Surgery and Metabolism 10/10/20151.
Riverside Medical and Surgical Weight Loss Center David Salzberg, M. D
BPD-DS & Sleeve Gastrectomy Journal Club Goal: To review 4 important and clinically relevant papers from 2010 on BPD-DS or Sleeve Gastrectomy 4 papers;
Metabolic and Bariatric Surgery: Expected Outcomes, Merits
Single Incision Bariatric Surgery Ninh T. Nguyen, MD, FACS University of California, Irvine Medical Center, Orange, CA.
When ? Indications Contraindications ?. When ? Indications Contraindications ?
Metabolic Effects of Bariatric Surgery
MISS Journal Club 2012 RYGB/BPD-DS Goal: to review 4 important and clinically relevant papers from 2011 on Gastric Bypass & BPD-DS.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Impact of early surgery vs conventional treatment for infective endocarditis on mortality and embolic events: data from EASE trial Prospective RCT ( );
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery Nancy A. Nussmeier, M.D., Andrew A. Whelton, M.D., Mark T. Brown,
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355: Steven E. Kahn,
Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.
Diabetes Prevention Program (DPP)
Gastric Bypass: Continuing Issues Walter J. Pories, MD, FACS Professor of Surgery, Biochemistry, Sport and Exercise Science Brody School of Medicine East.
An initiative of South Asian Federation of Endocrine Societies (SAFES)
Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:
Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes NEJM April 26, 2012 Diabetes Journal Club Sanaz Sakiani, MD.
Metabolic Surgery: Treating Type 2 Diabetes & Cardiovascular Risk in Obese Patients Highlights of Evidence from Recent Studies NAME DATE ©2012 Ethicon.
Bariatric Surgery for T2DM The STAMPEDE Trial. A.R. BMI 36.5 T2DM diagnosed age 24 On Metformin, glyburide  insulin Parents with T2DM, father on dialysis.
Philip R. Schauer, M.D., Deepak L. Bhatt, M.D., M.P.H., John P. Kirwan, Ph.D., Kathy Wolski, M.P.H., Stacy A. Brethauer, M.D., Sankar D. Navaneethan, M.D.,
(p for noninferiority = 0.01)
Hippocrates Prize Prof A. Kokkinos (Greece).
Treating Type 2 Diabetes in Obese Patients with Bariatric Surgery
The Cardiovascular Pipeline
Copyright © 2014 American Medical Association. All rights reserved.
ACCORD Design and Baseline Characteristics
Key publication slides
(Fig A reproduced with permission from Cummings DE, et al: Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl.
GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.
Geltrude Mingrone, M. D. , Simona Panunzi, Ph. D
Section overview: Cardiometabolic risk reduction
(p = 0.32 for noninferiority)
Enrollment and Outcomes
Results of the STAMPEDE Trial
Flow of Patients Through Trial
A: Forest plot of Peto odds ratios (ORs) of main glycemic end points, as defined in each trial, from published RCTs of bariatric/metabolic surgery compared.
Presentation transcript:

Metabolic Surgery for Type 2 Diabetes Robin Blackstone, MD, FACS, FASMBS President, ASMBS

STAMPEDE Trial 150 patients with type 2 diabetes BMI 27-43kg/m2, 1/3 BMI <35 Duration of Diabetes 8 years average, mean baseline HgA1C 8.9-9.5%, on 3 diabetic agents including 44% on insulin Randomized Prospective Trial Intensive Medical Therapy vs. Sleeve Gastrectomy vs. Gastric Bypass Schauer PR et al. N Engl J Med 2012. DOI: 10.1056/NEJMoa1200225

Characteristics of the Patients at Baseline. Schauer PR et al. N Engl J Med 2012. DOI: 10.1056/NEJMoa1200225

Changes in Measures of Diabetes Control from Baseline. Figure 1. Changes in Measures of Diabetes Control from Baseline. Values for change in glycated hemoglobin (Panel A), change in fasting plasma glucose (Panel B), the average number of diabetes medications (Panel C), and change in body-mass index (BMI) (Panel D) were plotted at 3, 6, 9, and 12 months. Least-square means and standard errors from a repeated measures model are plotted for glycated hemoglobin, average number of medications, and BMI; medians and interquartile ranges are plotted for fasting plasma glucose. P values are for the comparison between each surgical group and the medical-therapy group and were calculated from a repeated-measures model that considers data over time. Schauer PR et al. N Engl J Med 2012. DOI: 10.1056/NEJMoa1200225

Primary Endpoints After one year……… Patients achieving HgA1c of 6.0 or less, whether one or off medications 12% of intensive medical treatment group 37% in sleeve gastrectomy 42% in gastric bypass Schauer PR et al. N Engl J Med 2012. DOI: 10.1056/NEJMoa1200225

Enrollment and Outcomes. Figure 1. Enrollment and Outcomes. Mingrone G et al. N Engl J Med 2012. DOI: 10.1056/NEJMoa1200111

Glycated Hemoglobin Levels during 2 Years of Follow-up. Figure 2. Glycated Hemoglobin Levels during 2 Years of Follow-up. Mingrone G et al. N Engl J Med 2012. DOI: 10.1056/NEJMoa1200111

Primary Endpoints After two years (93% follow up) No patient on medical therapy achieved remission Rates of complete remission of diabetes (FBG </=100mg/dl, HGA1c </=6.0% for at least one year without medications) CR 75% Gastric Bypass and 95% for BPD Surgical procedures achieved diabetes control independent of preoperative BMI and post operative weight loss Mingrone G et al. N Engl J Med 2012. DOI: 10.1056/NEJMoa1200111

Safety of Surgery Mortality Rate HCUP5 LABS1 Hernia6 Buchwald4 DeMaria3 Lap Cholecystectomy9 Appendectomy7 GI Obstruction8 CABG w/ cath10 Carotid Stent12 Drug Eluding Stent11 1) LABS Reporting Group N Engl J Med 2009;361:445-54 2) DeMaria et al Surg Obes and Relat Dis 2010 ;6:347-355 3)DeMaria et al Ann Surg. 2007;246(4):578-82 4)Buchwald et al JAMA. 2004;292:1724-1737 5) AHRQ, Healthcare Cost and Utilization Project (HCUP), http://hcupnet.ahrq.gov/ accessed 01/13/10, 2007 data DRG 288 6) Ibid 2007 data DRG’s 161 and162 7 )Ibid 2007 data DRG’s 166 and167 8) Ibid 2007 data DRG’s 180 and181 9) Ibid 2007 data DRG’s 493 and 494 10) Ibid 2007 data DRG’s 547 and 548 11) Ibid 2007 data DRG’s 557 and 558 12 Ibid 2007 data DRG 577